Two Sigma Investments LP Sells 96,282 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Two Sigma Investments LP trimmed its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 35.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 173,753 shares of the company's stock after selling 96,282 shares during the period. Two Sigma Investments LP owned approximately 0.27% of Kymera Therapeutics worth $6,990,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Northern Trust Corp raised its stake in Kymera Therapeutics by 14.0% during the 4th quarter. Northern Trust Corp now owns 437,833 shares of the company's stock valued at $17,614,000 after buying an additional 53,658 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Kymera Therapeutics by 5.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 387,187 shares of the company's stock worth $15,577,000 after acquiring an additional 20,346 shares during the period. Victory Capital Management Inc. increased its position in Kymera Therapeutics by 174.2% during the fourth quarter. Victory Capital Management Inc. now owns 19,899 shares of the company's stock valued at $801,000 after acquiring an additional 12,643 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Kymera Therapeutics by 7.5% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,960 shares of the company's stock valued at $1,163,000 after acquiring an additional 2,011 shares during the last quarter. Finally, Wells Fargo & Company MN lifted its holdings in Kymera Therapeutics by 51.8% in the fourth quarter. Wells Fargo & Company MN now owns 21,939 shares of the company's stock valued at $883,000 after acquiring an additional 7,487 shares during the period.

Kymera Therapeutics Trading Down 3.0%

KYMR traded down $0.92 on Friday, hitting $29.34. 89,386 shares of the company's stock traded hands, compared to its average volume of 566,309. Kymera Therapeutics, Inc. has a one year low of $19.45 and a one year high of $53.27. The firm has a market cap of $1.91 billion, a price-to-earnings ratio of -12.58 and a beta of 2.18. The company's 50 day simple moving average is $28.63 and its 200-day simple moving average is $35.89.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its earnings results on Friday, May 9th. The company reported ($0.82) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.10. The firm had revenue of $22.10 million for the quarter, compared to analysts' expectations of $11.38 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The business's revenue was up 114.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.69) earnings per share. As a group, equities analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Insider Activity

In other Kymera Therapeutics news, CFO Bruce N. Jacobs sold 7,035 shares of the business's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $214,215.75. Following the completion of the sale, the chief financial officer now directly owns 201,886 shares of the company's stock, valued at $6,147,428.70. The trade was a 3.37% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Ellen Chiniara sold 2,241 shares of Kymera Therapeutics stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $68,238.45. Following the sale, the insider now directly owns 80,085 shares of the company's stock, valued at approximately $2,438,588.25. This trade represents a 2.72% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 10,659 shares of company stock worth $324,567. 16.01% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

KYMR has been the subject of a number of recent research reports. Bank of America cut their price target on Kymera Therapeutics from $47.00 to $44.00 and set a "neutral" rating for the company in a research note on Monday, May 12th. HC Wainwright boosted their target price on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the company a "buy" rating in a research report on Friday, February 28th. UBS Group decreased their price target on shares of Kymera Therapeutics from $72.00 to $70.00 and set a "buy" rating on the stock in a research report on Tuesday, May 13th. Wall Street Zen upgraded shares of Kymera Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Finally, Guggenheim restated a "buy" rating and issued a $52.00 price objective on shares of Kymera Therapeutics in a research note on Monday, May 12th. Five analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $55.25.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.